Table 1 Descriptive information of interview participants
Participant | Age Range (years) | Pre/Post Transition | Diagnosis |
|---|---|---|---|
1 | 25–27 | Post | Leukemia |
2 | 25–27 | Post | Lymphoma |
3 | 25–27 | Post | Leukemia |
4 | 25–27 | Post | Lymphoma |
5 | 25–27 | Pre | Sarcoma |
6 | 18–19 | Pre | Lymphoma |
7 | > 27 | Post | Sarcoma |
8 | 22–24 | Pre | Sarcoma |
9 | 25–27 | Post | Lymphoma |
10 | 20–21 | Pre | Sarcoma |
11 | 22–24 | Pre | Hematologic Condition Treated with Bone Marrow Transplant |
12 | 25–27 | Pre | Sarcoma |
13 | 22–24 | Pre | Sarcoma |
14 | > 27 | Post | Leukemia |
15 | 20–21 | Pre | Central Nervous System Malignancy |
16 | 22–24 | Post | Central Nervous System Malignancy |
17 | 20–21 | Pre | Leukemia |
18 | 25–27 | Pre | Leukemia |
19 | 22–24 | Pre | Leukemia |
20 | 18–19 | Pre | Leukemia |
21 | 20–21 | Pre | Neuroblastoma |
22 | 20–21 | Pre | Central Nervous System Malignancy |
23 | 18–19 | Pre | Hematologic Condition Treated with Bone Marrow Transplant |
24 | 20–21 | Post | Lymphoma |
25 | 22–24 | Pre | Hematologic Condition Treated with Bone Marrow Transplant |
26 | 25–27 | Post | Sarcoma |
27 | > 27 | Post | Lymphoma |
28 | 25–27 | Pre | Lymphoma |
29 | 22–24 | Pre | Sarcoma |